| 1. Accepted major perpetrators | 2. Rejected perpetrators | 3. Unclassifiable | 4. Full table |
perhexaline is a strong inhibitor of CYP2D6.
|Strong inhibitors||bupropion  |
- Strong inhibitors: ≥ 5-fold increase in AUC or ≥ 80% decrease in clearance of in vivo CYP probe.
Footnotes and References
|1.||Kotlyar M, Brauer LH, Tracy TS, Hatsukami DK, Harris J, Bronars CA, Adson DE. Inhibition of CYP2D6 activity by bupropion. Journal of Clinical Psychopharmacology 2005; 25: 226-29.[PubMed]|
|2.||Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoexetine and tricyclic antidepressant interaction. Clinical Pharmacology & Therapeutics 1992; 51: 239-48.[PubMed]|
|3.||Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J, Chung M. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. Journal of Clinical Psychopharmacology 1997; 17: 284-91.[PubMed]|
|4.||Davies BJL, Coller JK, James HM, Gillis D, Somogyi AA, Horowitz JD, Morris RG, Sallustio BC. Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline. British Journal of Clinical Pharmacology 2004; 57: 456-63.[PubMed]|
DisclaimerWARNING: While all efforts were put in to maintain the accuracy and currency of the information, it is possible that the knowledge and electronic tools may contain errors and inadequacy. Both Flinder's University and University of New South Wales are not liable to any damages or losses resulted from such circumstances. Clinical discretions are strongly advised at all times.